Petros Pharmaceuticals, Inc. (29)

Browse by Contract Category

Contracts

Amendment No. 1 to License and Commercialization Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on May 16, 2022)
Promissory Note, dated January 18, 2022, by Metuchen Pharmaceuticals LLC in favor or VIVUS LLC, a Delaware limited liability company (Filed With SEC on May 16, 2022)
Settlement Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on May 16, 2022)
Severance and General Release Agreement, dated March 1, 2022, between Andrew Gesek and Petros Pharmaceuticals, Inc., its affiliates, subsidiaries and successor entities (Filed With SEC on March 4, 2022)
Letter Agreement, dated as of March 31, 2021, by and between Metuchen Pharmaceuticals, LLC and Hybrid Medical LLC (Filed With SEC on April 6, 2021)
DESCRIPTION OF CAPITAL STOCK (Filed With SEC on March 31, 2022)
Amendment No. 1 to License and Commercialization Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
Security Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
Promissory Note, dated January 18, 2022, by Metuchen Pharmaceuticals LLC in favor or VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
Settlement Agreement, dated January 18, 2022, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company (Filed With SEC on January 21, 2022)
Form of Securities Purchase Agreement (Filed With SEC on December 27, 2021)
Form of Warrant (Filed With SEC on December 27, 2021)
Second Amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan (Filed With SEC on December 23, 2021)
Form of Warrant (Filed With SEC on December 1, 2021)
Form of Securities Purchase Agreement (Filed With SEC on December 1, 2021)
Form of Securities Purchase Agreement (Filed With SEC on October 15, 2021)
Form of Investor Warrant (Filed With SEC on October 15, 2021)
Letter Agreement, dated as of September 24, 2020, by and between the Company and Hybrid Medical LLC (Filed With SEC on March 31, 2021)
License Agreement, dated as of March 14, 2020, by and between the Company and Hybrid Medical LLC (Filed With SEC on March 31, 2021)
Third Amendment to Loan and Security Agreement, dated as of September 30, 2020, by and between the Company, Pos-T-Vac, LLC, Timm Medical Technologies, LLC, the lenders a party... (Filed With SEC on March 31, 2021)
Second Amendment to Loan and Security Agreement, dated as of April 13, 2020, by and between the Company, Pos-T-Vac, LLC, Timm Medical Technologies, LLC, the lenders a party... (Filed With SEC on March 31, 2021)
First Amendment to Loan and Security Agreement, dated as of November 22, 2017, by and between the Company, the lenders a party thereto from time to time, and Hercules Capital, Inc (Filed With SEC on March 31, 2021)
Loan and Security Agreement, dated as of September 30, 2016, by and between the Company, the lenders a party thereto from time to time, and Hercules Capital, Inc (Filed With SEC on March 31, 2021)
Description of Capital Stock (Filed With SEC on March 31, 2021)
Form of Petros Pharmaceuticals, Inc. Nonqualified Stock Option Grant Agreement (Filed With SEC on February 25, 2021)
Employment Offer Letter, entered into as of February 19, 2021, by and between Petros Pharmaceuticals, Inc. and Fady Boctor (Filed With SEC on February 25, 2021)
Separation Agreement, entered into as of December 24, 2020, by and between the Company and Keith Lavan (Filed With SEC on December 31, 2020)
Bonus Agreement, entered into as of December 11, 2020, by and between Petros Pharmaceuticals, Inc. and Fady Boctor (Filed With SEC on December 15, 2020)
Registration Rights Agreement, dated as of December 1, 2020, by and among Petros Pharmaceuticals, Inc. and JCP III SM AIV, L.P (Filed With SEC on December 2, 2020)